GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 396 participants.
Also called NCT07617155
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 396 participants
- Registry
-
NCT07617155
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07617155. Randomized; quadruple masking; primary purpose prevention. Start 2026-09 (anticipated); primary completion 2028-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
- Acronym
- RECAP-GLP1
- Condition
- Hypertriglyceridemia Induced Acute Pancreatitis
- Condition
- Recurrent Acute Pancreatitis
- Condition
- Pancreatitis Relapsing
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (Normal Saline)
- Lead sponsor
- Peking Union Medical College Hospital
Record details
- Record id
cardio:ct-nct07617155- Content hash
cfb0db86195a467855e1fb8d21608dffeb9a7028269af12a65ab1728d0a43c81